Kirkland Advises CD&R on Potential Partnership with Sanofi to Acquire Opella

Kirkland & Ellis is advising CD&R on the M&A and reinvestment aspects as it enters into exclusive negotiations with Sanofi to acquire a 50% controlling stake in consumer healthcare champion, Opella, with Sanofi remaining a significant shareholder. CD&R’s acquisition of a controlling stake values Opella at approximately €16 billion (EV). Headquartered in France, Opella employs over 11,000 people, operates in 100 countries with 13 strategic manufacturing sites and four science and innovation development centers. Opella is the third-largest business worldwide in the over-the-counter and vitamins, minerals & supplements market, serving more than half a billion consumers worldwide.